TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President and CEO: Yoshihiro Arai, hereinafter “Solasia”) an oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the approval for listing of shares on the Tokyo Stock Exchange (TSE) Mothers.
The scheduled date of the listing of the shares is Friday March 24, 2017, on or after which date the shares will be available for trading on the TSE Mothers.
The proceeds from this offering will be directed primarily to development and commercialization activities, and to execute on the company’s mission of providing “Better medicine for a brighter tomorrow”.